Regarding the latter, NCI researchers and Novartis were the first to develop potent ANTXR1-specific mAbs using phage display libraries and to test the anticancer efficacy of these mAbs in preclinical xenograft mouse models of colon cancer and in a syngeneic mouse model of melanoma [44]. The gene discussed is ANTXR1; the disease is colonic neoplasm.